Clinical Trials Logo

STEMI clinical trials

View clinical trials related to STEMI.

Filter by:

NCT ID: NCT03037229 Completed - STEMI Clinical Trials

Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction

ST LEUIS
Start date: December 29, 2016
Phase:
Study type: Observational

Is the Smartphone ECG (electrocardiogram) an acceptable replacement for a standard ECG in the identification of STEMI (ST Elevation Myocardial Infarction).

NCT ID: NCT03016611 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study

Start date: February 2017
Phase: Phase 4
Study type: Interventional

To examine the efficacy of chewing Ticagrelor versus Prasugrel in ST-elevation Myocardial Infarction (STEMI) patients on platelet reactivity.

NCT ID: NCT03000270 Completed - STEMI Clinical Trials

Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction - Safety and Feasibility Study

DTU
Start date: April 11, 2017
Phase: N/A
Study type: Interventional

Direct active unloading of the left ventricle with the Impella CP System prior to PPCI in patients with ST-elevation myocardial infarction (STEMI) is safe and feasible

NCT ID: NCT02982057 Completed - STEMI Clinical Trials

Non Culprit Lesion Study

Start date: January 2015
Phase: Phase 3
Study type: Interventional

The aim of the present study is to compare the evolution of non culprit lesions after treatment by BVS versus optimal medical therapy at 2-years follow- up

NCT ID: NCT02943369 Completed - STEMI Clinical Trials

Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI

Start date: July 28, 2017
Phase: Phase 4
Study type: Interventional

Platelets and thrombus formation play a key role in the pathogenesis of acute coronary artery occlusion and subsequent myocardial infarction. Apart from mechanically opening the occluded artery with angioplasty, adjunctive antiplatelet treatment is of utmost importance. However, orally administered antiplatelet agents exhibit a delay in their onset of action in the setting of acute myocardial infarction and angioplasty is mostly performed without adequate platelet inhibition. Cangrelor is an intravenous antiplatelet agent which can provide almost immediate strong platelet inhibition. The investigators aim to compare a strategy of cangrelor administered on top of ticagrelor-an oral antiplatelet agent- vs ticagrelor alone, on their efficacy to inhibit platelet function in the early hours of an acute myocardial infarction.

NCT ID: NCT02942550 Completed - STEMI Clinical Trials

Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients

MOVEMENT
Start date: November 2016
Phase: Phase 4
Study type: Interventional

This study will examine the impact of the peripheral opioid antagonist methylnaltrexone on the onset of effect of ticagrelor in morphine treated patients with ST elevation myocardial infarction (STEMI). Half of the participants will receive methylnaltrexone, while the other half will receive placebo.

NCT ID: NCT02926755 Completed - Clinical trials for Coronary Artery Disease

Multi-modality Imaging in Acute Myocardial Infarction

MIAMI
Start date: January 20, 2016
Phase: N/A
Study type: Interventional

The goal of this study is to use three (3) different imaging techniques:Fractional Flow Reserve (FFR) allows precise measurement of blood flow in the arteries to the heart, and is more reliable than pictures alone to determine the significance of blockages in the heart; Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume; and Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; to evaluate high risk non-infarct-related coronary lesion in patients who have suffered a recent heart attack, underwent successful opening of the artery with a stent, and have blockages greater than or equal to 50% in one or more of the other arteries to the heart; and to correlate this findings with cardiovascular outcomes at 1 year.

NCT ID: NCT02871622 Not yet recruiting - Clinical trials for Coronary Artery Disease

BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM

Start date: September 2016
Phase: N/A
Study type: Observational [Patient Registry]

Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data collection. Major adverse cardiac events (MACE) results at 9 months will be compared to the results obtained from the BioMatrix FlexTM arm of the LEADERS trial.

NCT ID: NCT02849691 Completed - Bleeding Clinical Trials

Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding

Start date: January 2014
Phase: N/A
Study type: Observational

Dipeptidyl-peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (AMI). However clinical data of DPP4a in AMI patients is sparse. This study was to investigate the role of plasma DPP4 activity (DPP4a) in patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). This was a analysis of consecutive patients conducted at a tertiary referral center from January 2014 to October 2015. The investigators included 747 STEMI-patients, treated with PCI from January 2013 to October 2015. Blood samples were collected immediately at admission. The patients were divided into four groups according to DPP4a quartile.

NCT ID: NCT02792920 Recruiting - STEMI Clinical Trials

Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction

XIENCE STEMI
Start date: March 2016
Phase: N/A
Study type: Interventional

To compare early and late clinical outcomes with everolimus-eluting cobalt-chromium stent in patients with ST-elevation acute myocardial infarction, as well as identify the characteristics and efficacy of CoCr-EES. Also, OCT sub-analysis will be conducted